Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323748 · ClinicalTrials.gov registry record · Phase 1
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
A Phase 1 study, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04323748 is a Phase 1 study that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants.
The verdict
NCT04323748, a Phase 1 study, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
Interventions
- DRUG rituxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04323748
The ClinicalTrials.gov registry entry for NCT04323748 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituxan is the first listed.
NCT04323748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04323748 about?
NCT04323748 is a clinical study titled "Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura". The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be mea...
What is the current status of trial NCT04323748?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-02-24. Estimated completion is 2027-07-31.
What interventions are being tested in trial NCT04323748?
The interventions under investigation include: rituxan (DRUG).
Who is sponsoring clinical trial NCT04323748?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.